Showing results (2081-2090 of 2,114) with videos related to
Sort By:
Pageof 212
BMJ Paediatrics Open|June 29, 2023
Parental detection of neonatal jaundice using a low-cost colour card: a multicentre prospective studyGuochang Xue, Huali Zhang, Xuexing Ding, et al.BMC Plant Biology|December 1, 2022
OrchidBase 5.0: updates of the orchid genome knowledgebaseYou-Yi Chen, Chung-I Li, Yu-Yun Hsiao, et al.Scientific Data|June 21, 2024
SARS-CoV-2 viral titer measurements in Ontario, Canada wastewaters throughout the COVID-19 pandemicPatrick M D'Aoust, Nada Hegazy, Nathan T Ramsay, et al.Nature Communications|May 8, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2)Weiping Jia, Fei Gao, Jingyi Lu, et al.BMC Plant Biology|January 3, 2025
OrchidBase 6.0: increasing the number of Cymbidium (Orchidaceae) genomes and new bioinformatic tools for orchid genome analysisYou-Yi Chen, Ye Sun, Chung-I Li, et al.European Journal of Medicinal Chemistry|December 20, 2021
Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug designTeng-Kuang Yeh, Jen-Shin Song, Po-Wei Chang, et al.Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.Pageof 212